Bicycle Therapeutics PLC (BCYC) stock
Close on Nov 12, 2026Market cap $241.82MP/E –Yield 0.00%
Bicycle Therapeutics PLC grew revenue 194.7% to $83.53M over the twelve months to Sep 30, 2026. Free cash flow was -$177.04M. At the latest close the market valued the company at $241.82M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $241.82M
- P/E ratio
- –
- Price to sales
- 2.90
- Price to book
- 0.48
- Dividend yield
- 0.00%
- Free cash flow yield
- -73.21%
Fundamentals
- Revenue
- $83.53M
- Net income
- -$141.79M
- EPS, diluted
- -$2.03
- Free cash flow
- -$177.04M
- Book value per share
- $7.22
- Diluted shares
- 70M
Trading
- Next earnings
- Mar 16, 2027 (estimated, before the open)
- Previous close
- $3.69
- Open
- $3.65
- Day's range
- $3.43 – $3.66
- Volume
- 630,101
- Average volume (20 days)
- 408,886
- Beta (5 years)
- 1.39
- 52-week range
- $3.33 – $7.83
- RSI (14 days)
- 50.0
- Volatility (1 year)
- 50.6%
- Relative volume
- 0.44×
- WACC
- 11.8%
On 2 of our idea lists: Net-nets, More cash than they're worth
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | BCYC | S&P 500 | Difference | BCYC per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -9.2% | -2.7% | −6.5 pts | ||
| 3 months | -15.0% | -1.7% | −13.3 pts | ||
| Year to date | -51.3% | +11.9% | −63.2 pts | ||
| 1 year | -47.4% | +12.0% | −59.4 pts | ||
| 3 years | -74.0% | +78.2% | −152.2 pts | -36.2% | +21.2% |
| 5 years | -94.0% | +73.2% | −167.3 pts | -43.1% | +11.6% |
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Bicycle Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- Results
- News
- Results
About Bicycle Therapeutics
Pharmaceutical Preparations
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing synthetic bicyclic peptides, termed Bicycle molecules, to treat diseases with significant unmet medical need. The company utilizes a proprietary phage display screening platform to discover and engineer therapeutics across multiple drug modalities, including drug conjugates, radioconjugates, imaging agents, and immune cell agonists. Its primary internal pipeline centers on oncology, led by product candidates such as nuzefatide pevedotin and the radiopharmaceutical BT1702. In addition to internal discovery, the company collaborates with external biopharmaceutical partners to develop therapies across various disease indications, including cardiometabolic, central nervous system, and neuromuscular conditions.
Company profile, executives and historyBicycle Therapeutics stock: common questions
What is Bicycle Therapeutics's stock price?
BCYC closed at $3.45 on Nov 12, 2026, down 6.50% on the day. Over the past 52 weeks it traded between $3.33 and $7.83.
What is Bicycle Therapeutics's market cap?
Bicycle Therapeutics was worth $241.82M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is BCYC's P/E ratio?
Bicycle Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.03), so it has no meaningful P/E ratio.
How much revenue does Bicycle Therapeutics make?
Bicycle Therapeutics reported revenue of $83.53M for the twelve months to Sep 30, 2026, up 194.7% from a year earlier.
Does Bicycle Therapeutics pay a dividend?
No. Bicycle Therapeutics has not paid a cash dividend over the last twelve months.
When does Bicycle Therapeutics report earnings next?
Bicycle Therapeutics is expected to report Q4 FY2026 results on Mar 16, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has BCYC stock performed over the past year?
Including dividends, BCYC returned -47.4% over the past year, against +12.0% for the S&P 500.
Who are Bicycle Therapeutics's competitors?
Companies most similar to Bicycle Therapeutics by business, industry and size include AMLX, PRTA, RCUS, FHTX, WVE.
See a number that looks wrong?